Immunogenic ALK peptides
OwnerCarlo Gambacorti-Passerini, Lorena Passoniinventors
Life of this patent
Estimating the term…
Abstract
There are disclosed immunogenic peptides from Anaplastic Lymphoma Kinase (ALK), methods in vivo or in vitro for activating ALK-specific CTLs and for stimulating an immune response against tumors, and pharmaceutical compositions containing ALK peptides for tumor immunotherapy.
Claims21
An HLA-A*0201-binding ALK peptide selected from the group consisting of:
- SEQ ID NO:
- 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 SEQ ID NO:7.
A monoclonal or polyclonal antibody, or an active fragment thereof, that selectively recognizes an ALK peptide selected from the group consisting of the peptides set forth in SEQ ID NOS:
- 1-7.
An isolated T lymphocyte which selectively binds a complex of an HLA-class I molecule and an ALK peptide selected from the group consisting of SEQ ID NOS:1-7.
A method for treating a subject having a disorder characterized by the expression of an ALK antigen, which comprises administering to the subject an effective amount of an ALK peptide selected from the group consisting of SEQ ID NOS:
- 1-7, or a functional variant thereof, or an amount of antigen presenting cell carrying such a peptide, or of autologous T lymphocytes specific for complexes of an HLA-A*0201 molecule and a ALK peptide as above specified, or a functional variant thereof.
An isolated nucleic acid encoding an HLA-A*0201-binding ALK peptide selected from the group consisting of SEQ ID NOS:
- 1-7.
An isolated nucleic acid encoding an HLA-A*0201-binding ALK peptide set forth in SEQ ID NO:1 or SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.